Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02767921 · ClinicalTrials.gov registry record · Phase 1
sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer
A Phase 1 study, sponsored by University of Southern California.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT02767921 is a Phase 1 study that was terminated before completion, run by University of Southern California. The registered enrollment target is 2 participants.
The verdict
NCT02767921, a Phase 1 study, was terminated before completion, sponsored by University of Southern California.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This pilot clinical trial studies the side effects of recombinant EphB4-HSA fusion protein before surgery in treating patients with transitional cell carcinoma of the bladder, prostate cancer, or kidney cancer. Recombinant EphB4-HSA fusion protein may block an enzyme needed for tumor cells to multiply and may also prevent the growth of new blood vessels that bring nutrients to the tumor. Giving recombinant EphB4-HSA fusion protein before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
Interventions
- OTHER Laboratory Biomarker Analysis
- OTHER Cytology Specimen Collection Procedure
- PROCEDURE Therapeutic Conventional Surgery
- PROCEDURE Radical Cystectomy
- BIOLOGICAL Recombinant EphB4-HSA Fusion Protein
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2016-08-02 |
| Est. Completion | 2021-11-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02767921
The ClinicalTrials.gov registry entry for NCT02767921 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02767921 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02767921 about?
NCT02767921 is a clinical study titled "sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer". This pilot clinical trial studies the side effects of recombinant EphB4-HSA fusion protein before surgery in treating patients with transitional cell carcinoma of the bladder, prostate cancer, or kidney cancer. Recombinant EphB4-HSA fusion protein may block an enzyme needed for tumor cells to multip...
What is the current status of trial NCT02767921?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2016-08-02. Estimated completion is 2021-11-15.
What interventions are being tested in trial NCT02767921?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Cytology Specimen Collection Procedure (OTHER), Therapeutic Conventional Surgery (PROCEDURE), Radical Cystectomy (PROCEDURE), Recombinant EphB4-HSA Fusion Protein (BIOLOGICAL).
Who is sponsoring clinical trial NCT02767921?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.